Skip to main content

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs Regional

A CME-certified, ABIM MOC and MIPS-eligible Activity

TO REGISTER
Click here to complete your registration.


If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

DATES AND TIMES

Thursday, October 6, 2022

6:00 - 7:00 PM CT (7:00 - 8:00 PM ET / 4:00 - 5:00 PM PT)

Wednesday, December 7, 2022
5:15 - 6:15 PM CT (6:15 - 7:15 PM ET / 3:15 - 4:15 PM PT)

Thursday, December 8, 2022
6:00 - 7:00 PM CT (7:00 - 8:00 PM ET / 4:00 - 5:00 PM PT)

AGENDA

  • Welcome and Introductions
  • Pathophysiology of Anemia in Chronic Kidney Disease
  • Health Outcomes, Quality of Life, and Functioning in Patients with Chronic Kidney Disease and Anemia
  • Current Management of Anemia in Chronic Kidney Disease
  • Agents in Late-Stage Development for Managing Anemia in Chronic Kidney Disease
  • Q&A Session

PROGRAM DESCRIPTION

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events.

Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs will provide cardiologists with information about the etiology of anemia in CKD, the effects on CV disease, HRQOL, and function, advantages and limitations of current management strategies, and the efficacy and safety data for HIF-PHIs in late-stage development for the management of CKD-related anemia.

STEERING COMMITTEE
Erin Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Professor of Medicine and Epidemiology
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Heart Disease
Division of Cardiology, Johns Hopkins School of Medicine
Baltimore, MD


Matthew Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD


TARGET AUDIENCE
This activity is intended for cardiologists, who are clinicians responsible for managing patients with cardiovascular disease and chronic kidney disease.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to:
  • Discuss the etiology of anemia in chronic kidney disease
  • Summarize how anemia affects functioning, quality of life, and health outcomes, for patients with cardiovascular disease and chronic kidney disease
  • Assess the benefits and limitations of available modalities for treating anemia in chronic kidney disease
  • Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of anemia of chronic kidney disease

PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT
USF Health designates this live activity activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about accreditation of this activity, please email: cpdsupport@health.usf.edu.

ABIM MOC RECOGNITION STATEMENT
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is USF Health’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through USF Health’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Participants will earn MOC Points equivalent to the amount of CME credits claimed for the activity. USF Health will submit within 60 days the Participant’s MOC Points. No MOC certificates will be provided. Participants with questions regarding their Points, should contact USF Health at cpdsupport@usf.edu 

MIPS CREDIT DESIGNATION STATEMENT
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

DISCLOSURE INFORMATION
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

PROGRAM FACULTY
The faculty, authors, and content developers reported the following relevant financial relationships with ineligible companies:
Erin D. Michos, MD- Advisory Board or Panel: AstraZeneca, Bayer, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, Pfizer

Matthew Weir, MD- Advisory Board or Panel: Boehringer Ingelheim, Novo Nordisk, Bayer, Merck, AstraZeneca, GSK, Janssen, Vifor, and Akebia.

PLANNERS AND MANAGERS
The planners and mangers reported the following relevant financial relationships with ineligible companies:
Terry A. Glauser, MD, MPH: No relevant financial relationships to disclose
USF Health OCPD Staff: No relevant financial relationships to disclose.

NURSE PLANNER AND CONTENT REVIEWER
The Nurse Planner and content reviewer report the following relevant financial relationships with ineligible companies:
Alicia Ann Canalejo, MSN, ARNP-C: No relevant financial relationships to disclose

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

HARDWARE REQUIREMENTS
WINDOWS

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
MAC OS
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
MOBILE
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

SOFTWARE REQUIREMENTS
DSL/cable (wired connection recommended)

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT AND MOC POINTS
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you have questions regarding credit please contact cpdsupport@usf.edu

Jointly provided by USF Health and Rockpointe

  

This educational activity is supported by an educational grant from GlaxoSmithKline.

The information provided by this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF Health is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CE to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by Rockpointe and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by Rockpointe or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in Rockpointe or USF Health activities. Rockpointe and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals.



PCME Privacy Policy